CTCL Expert Perspectives
POTELIGEO Efficacy and Safety
Hear Andrei Shustov, MD discuss the value of key endpoints used in the phase 3 MAVORIC trial, patient types appropriate for treatment with POTELIGEO, and the most common adverse reactions reported in MAVORIC.
Andrei Shustov, MD discusses identifying therapy-refractive patients, how blood involvement can impact treatment selection, how clinical practice guidelines help shape decisions, and appropriate patient types for treatment with POTELIGEO based on data from the phase 3 MAVORIC trial.
Lauren C. Pinter-Brown, MD, clinical professor of Hematology/Oncology at the University of California, Irvine, discusses how to communicate with patients who have mycosis fungoides (MF) or Sézary syndrome (SS) on topics including disease state, prognosis, blood involvement, staging, and prescribing.
How POTELIGEO Works
POTELIGEO Mechanism of Action
Learn about how POTELIGEO works, POTELLIGENT® technology, the role of C-C chemokine receptor type 4 (CCR4),1 and key points of the infusion process.
Explore POTELLIGENT technology, an innovative approach designed to enhance antibody-dependent cellular cytotoxicity.
POTELIGEO and the CCR4 Target
Learn why CCR4 is a key target for mycosis fungoides and Sézary syndrome, and how POTELIGEO targets CCR4-positive T cells.1
POTELIGEO® Points Virtual Library
Take a virtual tour of all things POTELIGEO with these short, information-packed vignettes.
The MAVORIC Trial Patient Population
Explore the diverse patient population and key efficacy results of POTELIGEO vs vorinostat.1
POTELIGEO Efficacy in Skin
Learn about the response of POTELIGEO in skin, based on a post hoc analysis of data in the MAVORIC clinical trial.1
How POTELIGEO Uniquely Targets CCR4
Learn about the role of C-C chemokine receptor type 4 (CCR4) in mycosis fungoides (MF) and Sézary syndrome (SS), and how POTELIGEO kills CCR4+ malignant T cells.1
Be sure to sign up so we can keep you informed of updates
and new materials in the POTELIGEO Digital Library.
- POTELIGEO [package insert]. Kyowa Kirin Inc., Bedminster, NJ USA.